SG/CALL/ASTRAZENECA/11000/0.1/20.09.24 | Market Closed - Börse Stuttgart 02:14:36 2024-06-07 am EDT | ||
| 2.12 EUR | +1.44% |
|
| Current month | +26.19% | ||
| 1 month | +21.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 2.12 | +1.44% |
| 24-06-06 | 2.09 | +1.46% |
| 24-06-05 | 2.06 | +10.75% |
| 24-06-04 | 1.86 | +6.90% |
| 24-06-03 | 1.74 | +3.57% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 02:14 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SU796U |
| ISIN | DE000SU796U6 |
| Date issued | 2024-02-13 |
| Strike | 11,000 p |
| Maturity | 2024-09-20 (104 Days) |
| Parity | 10 : 1 |
| Emission price | 0.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.12 € |
|---|---|
| Lowest since issue | 0.23 € |
| Spread | 0.13 € |
| Spread % | 5.96% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159.8
USD
Average target price
173.1
USD
Spread / Average Target
+8.38%
- Stock Market
- Warrants
- Warrant
